Free tool
FAERS Monitor: Ferabright
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219868 or its brand name (Ferabright, Ferumoxytol). Reports on generic versions are filed under their own applications.
Reports
239
Serious
178
74% of reports
Hospitalization
59
Death reported
20
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea66
- infusion related reaction65
- nausea33
- anaphylactic reaction28
- back pain22
- vomiting22
- dizziness20
- chest discomfort19
- flushing19
- hypotension17
- chest pain13
- hypertension13
- cardio-respiratory arrest11
- abdominal pain10
- headache10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 10 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 12 |
| 2019 | 15 |
| 2020 | 13 |
| 2021 | 24 |
| 2022 | 22 |
| 2023 | 16 |
| 2024 | 25 |
| 2025 | 37 |
| 2026 | 32 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,920 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 65 | 86.4 | 70.2 | 5,412 |
| anaphylactic reactionSignal | 28 | 44.6 | 31.5 | 1,153 |
| cardio-respiratory arrestSignal | 11 | 23.2 | 13.0 | 212 |
| flushingSignal | 19 | 16.5 | 10.7 | 262 |
| chest discomfortSignal | 19 | 16.3 | 10.6 | 260 |
| dyspnoeaSignal | 66 | 10.3 | 8.4 | 557 |
| back painSignal | 22 | 8.3 | 5.6 | 136 |
| hypotensionSignal | 17 | 7.5 | 4.7 | 90 |
| chest painSignal | 13 | 6.2 | 3.6 | 52 |
| hypertensionSignal | 13 | 5.4 | 3.2 | 43 |
| vomitingSignal | 22 | 4.1 | 2.8 | 50 |
| abdominal painSignal | 10 | 3.8 | 2.1 | 18 |
| nauseaSignal | 33 | 3.7 | 2.7 | 64 |
| dizzinessSignal | 20 | 3.5 | 2.3 | 35 |
| headache | 10 | 1.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.